Endovascular Revascularization of Below-the-Knee Arteries: Prospective Short-Term Angiographic and Clinical Follow-Up

Value of S100A12 in predicting in‑stent restenosis in patients with coronary drug‑eluting stent implantation

“…PCI with DES has revolutionized the treatment of patients with CAD over the past decade; however, its benefits are overshadowed by the occurrence of in-stent restenosis (1,2). Vascular inflammation has a pathogenetic role in the development of ISR after deployment of DES (3,5). It is generally accepted that the vascular inflammatory status prior to the intervention and the severity of the inflammatory reaction after the procedure are determinants of ISR (22).…”

“…The major trend of the current viewpoint supports inflammatory mechanisms of adverse responses to DES. It is suggested that the abnormal proliferation and migration of vascular smooth muscle cells (VSMCs), as well as extracellular matrix accumulation activated by various pro-inflammatory mediators and growth factors in response to local vascular injury, result in neointima formation and eventually lumen loss (3)(4)(5)(6). Therefore, identifying a specific, sensitive and non-invasive blood biomarker for predicting ISR is of clinical significance in order to select tailored management strategies, including the use of multiple stents or offering more prolonged anti-platelet therapy to patients with coronary artery disease (CAD) with an elevated risk of ISR.…”

Current Trends and outcomes: Endovascular Management in Arteriosclerosis Obliterans (ASO) of Lower Limb Vessels

“…[53,54,55] In diabetic patients extant and burden regarding infrapopliteal arterial diseases are well described in different literatures [56] , more over high post-PTA restenosis rates have also been consistently reported. [57,58,59] The impact of high infrapopliteal vessel restenosis rates are not clear on the prognosis of CLI patients, despite regarding high infrapopliteal PTA restenosis rates, the limb salvage rates appear more acceptable [60] when compared to open lower limb bypass. [61] Thus, there is an evolving impression, endorsed by societal guidelines [62,63] that favors potential near-term benefit of PTA as the "first line approach" in specific CLI patients in comparison to open surgery.…”

Clinical outcomes of lower limb peripheral vascular disease after endovascular intervention in patients with diabetes mellitus, critical limb ischemia and chronic kidney disease

“…Обращает внимание значительная вариабельность значений первичной и вторичной проходимости, полученных в различных исследованиях. Различная встречаемость нарушений проходимости после выполнения эндоваскулярных вмешательств может объясняться разнородностью по процентному соотношению пациентов с тяжелыми сопутствующими заболеваниями, в том числе с СД и ХБП [40][41][42][43][44][45]. В нашем исследовании первичная проходимость при наблюдении от 5 до 24 месяцев составила 59% в группе больных без нарушения выделительной функции почек и 38% в группе ХБП, что сопоставимо с данными других авторов.…”